http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018261890-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_262370c2c4e9ebe333924c282dd10db5
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0482
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08
filingDate 2018-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73d99d7b6c8d004da3907777e1747a1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c879b3c7d78fd41cb6032565528c337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d73fdead3132bac7ffd92eefe90f5f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b5140ba311daf6b4e66ead8389b964a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1b143d812d54da094cfa22d836502d2
publicationDate 2019-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2018261890-A1
titleOfInvention IGF-1R monoclonal antibodies and uses thereof
abstract The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof. The present invention is directed to monoclonal antibodies that target the insulin-like growth factor-1 receptor and the radioimmunoconjugates thereof that demonstrate increased potency and enhance the excretion of a chelating moiety, or a metal complex thereof, when conjugated to a therapeutic moiety, a targeting moiety, or a cross-linking group. In another aspect, the invention features a pharmaceutical composition comprising a compound of the invention; and a pharmaceutically acceptable excipient. In another aspect, the invention features a method of radiation treatment planning and/or radiation treatment, the method comprising administering to a subject in need thereof a compound or pharmaceutical composition of the invention.
priorityDate 2017-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466357258

Total number of triples: 31.